Mavacamten Patent Expiration
Mavacamten is Used for improving functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in NYHA class II-III. It was first introduced by Bristol Myers Squibb Co
Mavacamten Patents
Given below is the list of patents protecting Mavacamten, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Camzyos | US9181200 | Pyrimidinedione compounds | Jun 19, 2034 | Bristol |
| Camzyos | US9585883 | Pyrimidinedione compounds | Jun 19, 2034 | Bristol |
| Camzyos | USRE50050 | Pyrimidinedione compounds | Jun 19, 2034 | Bristol |
Mavacamten's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List